Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Influenza: early-phase trial registry
27 of 157 indexed Influenza trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #70 of 28,707 conditions by registered trial count.
157 US clinical trials · 27 currently recruiting · #70 of 28,707 conditions by registered trial count
Influenza: 157 US clinical trials tracked, 27 recruiting.
Influenza is the subject of 157 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 73 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 36 of these trials.
Enrollment posture brief
Registry condition influenza
OPEN 27 | RECR 17% | LATE 42 | EARLY 73 | RANK #70 | SPON 36
Volume-matched condition peers
Nearest open-share peer: Arthritis, Rheumatoid (17% recruiting · 29 trials)
Influenza lists 27 open slots (17% of 157 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Influenza on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Influenza is recruiting below its size-band peers.
27 of 157 indexed trials (17.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Influenza research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 36 of 157 trials (22.9%). 62 distinct sponsors appear on at least one study for this condition label.
-
Typical Influenza enrolment sits around 219 participants.
Median target enrolment is 219 among the 157 trials that report a genuine target (sentinel values excluded). 55 of those (35%) plan for fewer than 100 participants.
-
Influenza research is mostly interventional.
134 interventional and 23 observational studies make up this index (85.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
157 total, page 1 of 4
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Kaiser Permanente
NCT06029933
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
VA Office of Research and Development
NCT06160128
The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study
Scripps Translational Science Institute
NCT04336020
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
University of Colorado, Denver
NCT05832307
Respiratory Virus Sampling and Repository
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05266222
Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India
Boston University
NCT06168019
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01386424
Dime La VerDAD: Verify, Debunk, and Disseminate
University of Chicago
NCT06417762
Influenza Immunization in Adults Over Age 75
Johns Hopkins University
NCT02200276
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04772170
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
Hoffmann-La Roche
NCT06094010
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05947071
Immune Defense Protein Impact On Respiratory Immune Outcomes
Quantec
NCT07431840
Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
Washington University School of Medicine
NCT06848309
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Vanderbilt University Medical Center
NCT05215327
pH1N1 Blinded Challenge Study
National Institute of Allergy and Infectious Diseases (NIAID)
NCT07110532
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04794829
Systems Investigation of Vaccine Responses in Aging and Frailty
Yale University
NCT05291676
Bone Marrow and Peripheral Blood Immune Responses Study
Emory University
NCT05616546
Influenza Human Challenge Model
Emory University
NCT05332899
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
National Institute of Allergy and Infectious Diseases (NIAID)
NCT07169318
High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)
Vanderbilt University Medical Center
NCT07192458
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
M.D. Anderson Cancer Center
NCT04712539
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Henry M. Jackson Foundation for the Advancement of Military Medicine
NCT07287137
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
University of Alabama at Birmingham
NCT04101838
A/Texas Flu Challenge
Emory University
NCT06753474
H5N1 Milk Detection Study
Emory University
NCT06850298
Kaiser Permanente VACCination Improvement With Nudge-based CardiovAscular Targeted Engagement
Kaiser Permanente
NCT06571747
Kaiser Colorado Flu Nudge
Kaiser Permanente
NCT07372950
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
Cidara Therapeutics
NCT07159763
Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants
Children's Hospital Medical Center, Cincinnati
NCT05436184
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Sanofi Pasteur, a Sanofi Company
NCT06744205
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Massachusetts General Hospital
NCT05040659
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
Pfizer
NCT05160636
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
Vanderbilt University Medical Center
NCT04613206
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
The Geneva Foundation
NCT05765396
Association Between Gut Microbiome and Dietary Determinants and Vaccine Response
M.D. Anderson Cancer Center
NCT05239403
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05945485
Impact of High Dietary Fiber on Microbiome and Vaccine Responses
M.D. Anderson Cancer Center
NCT05565586
Exercise and COVID-19 Viral T-cell Immunity
University of Arizona
NCT05019456
Pilot Influenza Challenge Study
Daniel Hoft, MD, PhD
NCT07063849
Mail Outreach To Increase Vaccination Acceptance Through Engagement
Brigham and Women's Hospital
NCT02243774
Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
Sanofi Pasteur, a Sanofi Company
NCT04460781
Patient Portal Flu Vaccine Reminders (RCT 6)
University of California, Los Angeles
NCT06062264
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects
Novartis Vaccines
NCT00630331
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
Medicago
NCT03301051
Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration
American Pharmacists Association Foundation
NCT03372967
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
Cidara Therapeutics
NCT06609460
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
GlaxoSmithKline
NCT00616928
Study to Evaluate Impact of School-based Influenza Vaccination on School Populations
Children's Hospital Los Angeles
NCT00844051
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 42 |
| Phase 2 | 31 |
| Phase 3 | 17 |
| Phase 4 | 25 |
Top Sponsors
Named interventions
Most-linked intervention names on Influenza records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Influenza trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Influenza page
157 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Influenza trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Influenza trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Influenza condition card totals 157 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.